Press release
Age-related Macular Degeneration Market to Accelerate Substantially by 2032, estimates DelveInsight
Key Takeaways from the Age-related Macular Degeneration Market Report
* The increase in Age-related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Age-related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
* The leading Age-related Macular Degeneration Companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
* Promising Age-related Macular Degeneration Therapies in the various stages of development include Anecortave Acetate 15 mg sterile suspension, Triamcinolone Acetate 4 mg, rhuFab V2 (ranibizumab), NG101 AAV gene therapy, Intravitreal Aflibercept Injection, and others.
* May 2024:- Neuracle Genetics Inc.- This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
* January 2024:- Acer Medical Inc.- An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD's automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.
* January 2024:- i-Lumen Scientific, Inc.- Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD). The i-Lumen(TM) AMD device is for in-office therapy use to deliver microcurrent electrical stimulation transpalpebrally (via the eyelid) for use by an ophthalmologist. The i-Lumen AMD device contains proprietary software with preset treatment algorithms and is calibrated at each session to the individual participant.
Discover which therapies are expected to grab the Age-related Macular Degeneration Market Share @ Age-related Macular Degeneration Market Outlook [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a common eye condition that affects the macula, which is the central part of the retina responsible for sharp, central vision needed for activities like reading and driving. AMD typically occurs in older adults and gradually worsens over time, leading to a loss of central vision. There are two main types of AMD: dry AMD, which involves the breakdown of light-sensitive cells in the macula, and wet AMD, which involves the growth of abnormal blood vessels underneath the macula.
Age-related Macular Degeneration Epidemiology Insights
The epidemiology section of Age-related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Age-related Macular Degeneration Epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Drugs Market
The Age-related Macular Degeneration Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Age-related Macular Degeneration signaling in Age-related Macular Degeneration are likely to uncover new therapeutic targets and further expand treatment options for patients.
Age-related Macular Degeneration Treatment Market Landscape
The Age-related Macular Degeneration treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Age-related Macular Degeneration has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Age-related Macular Degeneration treatment guidelines, visit @ Age-related Macular Degeneration Treatment Market Landscape [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Market Outlook
The report's outlook on the Age-related Macular Degeneration market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Age-related Macular Degeneration therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Age-related Macular Degeneration drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Age-related Macular Degeneration market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Age-related Macular Degeneration Drugs Uptake
The drug chapter of the Age-related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Age-related Macular Degeneration.
Major Age-related Macular Degeneration Companies
Several Age-related Macular Degeneration Companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
Learn more about the FDA-approved drugs for Age-related Macular Degeneration @ Drugs for Age-related Macular Degeneration Treatment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Age-related Macular Degeneration Market Report
* Coverage- 7MM
* Age-related Macular Degeneration Companies- Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
* Age-related Macular Degeneration Therapies- Anecortave Acetate 15 mg sterile suspension, Triamcinolone Acetate 4 mg, rhuFab V2 (ranibizumab), NG101 AAV gene therapy, Intravitreal Aflibercept Injection, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market Drivers and Barriers
* Age-related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Age-related Macular Degeneration Drugs in development @ Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Wet AMD Market Overview at a Glance
4. Dry AMD Market Overview at a Glance
5. Wet AMD Market: Future Perspective
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Drugs of Wet AMD
13. Emerging Drugs of Dry AMD
14. AMD: Seven Major Market Analysis
15. Key Opinion Leaders' Views
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Market Access and Reimbursement of Wet AMD
20. Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-to-accelerate-substantially-by-2032-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-related Macular Degeneration Market to Accelerate Substantially by 2032, estimates DelveInsight here
News-ID: 3483201 • Views: …
More Releases from ABNewswire
Siyata Mobile YoY Revenues Increase 30%, Report Follows A $2.2 Million Order And …
Siyata Mobile (NASDAQ: SYTA) stock surged 11% after publishing two milestone deals for its revolutionary Push-to-Talk Over Cellular (PoC) SD7 handset. Investor interest swelled starting on Monday after SYTA announced its revolutionary handset will be included in FirstNet Registered 's 'Free Feature Phone for Life' promotion, offered in collaboration with AT&T (NYSE: T), which highlights the increasing early adoption of its SD7 handsets. Investors also likely responded enthusiastically to the…
La Rosa Holdings Reaffirms Target of $100 Million 2024 Exit Run Rate After Posti …
La Rosa Holdings Corp. (NASDAQ: LRHC) is demonstrating that exceptional investment opportunities can indeed be found at penny stock prices. At $1.34 yesterday, this one may be an opportunity too good to pass up. And they just fortified that argument.
Before the opening on Thursday, La Rosa published Q1 earnings [https://finance.yahoo.com/news/la-rosa-reports-117-over-123000072.html] that showed its growth trajectory is not just steepening but doing so at an accelerating pace. In fact, based on…
Roofing Company: Expertise in Metal Roofing for Long-lasting Protection
Metal roofing is a durable, eco-friendly, and visually appealing option in roofing solutions. Whether you're looking to fortify your home against the elements or enhance its curb appeal, metal roofing offers many benefits
Metal roofing [https://jtroofs.com/#Metal+roofing:~:text=in%20Roofing%20Installation%2C-,Metal%20Roofing,-%2C%20Gutter%20Installation%20%26%20Siding] is a durable, eco-friendly, and visually appealing option in roofing solutions. Whether you're looking to fortify your home against the elements or enhance its curb appeal, metal roofing offers many benefits. In this Roofing Company…
Ghaaneh Saffron Sets New Benchmark for Authenticity and Quality in Dubai's Saffr …
Dubai, UAE - 16 May, 2024 - Ghaaneh Saffron, a leading name in the saffron industry, is proud to announce its emergence as the premier saffron wholesaler in Dubai. With a commitment to quality, authenticity, and customer satisfaction, Ghaaneh Saffron is revolutionizing the saffron market in the region.
As the demand for high-quality saffron continues to rise, Ghaaneh Saffron stands out as a trusted supplier offering premium-grade Iranian saffron. With a…
More Releases for Macular
Macular Edema Treatment Market Growth Factors and Emerging Trends Forecast to 20 …
Global Macular Edema Treatment Market Analysis 2022-2028 Report provides strategists, marketers and senior management with the critical information they need to assess the global Macular Edema Treatment Market as it emerges from the Covid-19 shut down. The impact of Coronavirus (COVID-19) on global market has reinforced many trends already shaping the industry pre COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on multiple platforms.
This…
Macular Edema and Macular Degeneration Market Size, Analysis, Forecast to 2028 | …
Stratagem Market Insights have included the latest addition of a report titled Macular Edema and Macular Degeneration Market to its expansive repository. The report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses,…
Macular Pucker Treatment Market – Forecast to 2026
The findings reviewed by GME stated that the Global Macular Pucker Treatment Market would grow at a CAGR value of 6.9 percent from 2021 to 2026. The increasing rate of individuals above the age group of 50 with macular pucker issues drives growth of the macular pucker treatment market. Besides the increasing patient rate, launch of advanced treatment therapies and products have resulted in macular pucker treatment being one of…
Macular Edema and Macular Degeneration Market Share, Trends and Analysis, Growth …
Macular edema is a condition in which the retinal layers around the fovea is accumulated by the fluid that leads to the vision impairment and also might lead to the vision loss. Macular edema can be of two types, namely cystoid macular edema and diabetic macular edema. In addition to this, the macular degeneration is a condition in which the loss of vision occurs due to the retinal damage and…
Diabetic Macular Edema - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Diabetic Macular Edema - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes…
Growth Macular Edema Therapeutics Market: 2017 - 2025
Macula is oval yellowish area surrounding the center of retina in the eye. Macular edema is the state when fluid and protein start accumulating under macula resulting swelling in the eye. Due to this swelling, central vision of eye get distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). The retina is the light-sensitive tissue at the back of the eye…
